Myocardial Energy Substrate Shifts During Critical Illness

Abstract

Critical illness, encompassing conditions such as sepsis, acute respiratory distress syndrome (ARDS), and multiorgan failure, exerts profound effects on myocardial metabolism. The healthy myocardium primarily utilizes fatty acids for ATP production, but during critical illness, there is a well-documented shift toward increased glucose utilization, altered substrate preference, and metabolic inflexibility. This review synthesizes the latest evidence on the mechanisms and clinical relevance of myocardial energy substrate shifts in critically ill patients, highlighting implications for patient management and emerging therapeutic directions.

Introduction

The myocardium is an energetically demanding tissue, relying on continuous ATP production to sustain contractile function. Under physiologic conditions, fatty acids account for 60–80% of myocardial ATP production, with the remainder derived from glucose, lactate, and ketone bodies. However, in critical illness, the metabolic landscape shifts dramatically, reflecting both systemic and local factors such as inflammation, hypoxia, and neurohormonal activation. Recognition of these substrate shifts is essential for understanding myocardial dysfunction in the intensive care unit (ICU) and for developing metabolic interventions tailored to critically ill populations.

Epidemiology / Disease Burden

Cardiac dysfunction is a common and significant contributor to morbidity and mortality in critically ill patients. Studies indicate that up to 40% of septic patients develop some degree of myocardial dysfunction. These alterations in cardiac performance are frequently associated with disturbances in energy metabolism, which may be under-recognized due to overlapping presentations and diagnostic challenges. The global burden of critical illness is rising, with increasing numbers of patients requiring ICU support, thus amplifying the clinical importance of understanding myocardial metabolic adaptation during acute stress states.

Pathophysiology

During critical illness, systemic inflammation, hypoxemia, and catecholamine excess induce complex changes in myocardial substrate preference. The failing myocardium demonstrates a switch from fatty acid oxidation to increased reliance on glucose and, in some contexts, lactate and ketone bodies. This substrate shift is mediated by downregulation of peroxisome proliferator-activated receptor-α (PPAR-α), suppression of fatty acid transport proteins, and upregulation of glucose transporters (GLUT1/4). Mitochondrial dysfunction, oxidative stress, and impaired beta-oxidation further exacerbate energy deficits, promoting metabolic inflexibility and contributing to contractile dysfunction. Recent metabolomic studies have revealed accumulation of intermediates such as acylcarnitines and reduced tricarboxylic acid (TCA) cycle flux, corroborating impaired oxidative metabolism.

Risk Factors

Patients most at risk for maladaptive myocardial substrate shifts include those with pre-existing cardiac dysfunction, advanced age, diabetes mellitus, obesity, and chronic metabolic diseases. Severity and duration of critical illness, particularly in the context of sepsis or prolonged mechanical ventilation, further heighten susceptibility. Iatrogenic factors, such as catecholamine infusions and hyperglycemic management strategies, can potentiate substrate derangements. Genetic variability in key metabolic enzymes and transporters may also modulate individual responses to critical illness.

Clinical Features

Myocardial substrate shifts manifest clinically as impaired contractile reserve, reduced cardiac output, and increased susceptibility to arrhythmias. Patients may present with hypotension, elevated lactate levels, and evidence of global or regional wall motion abnormalities on echocardiography. Laboratory findings frequently reveal elevated biomarkers of myocardial injury and metabolic stress, including troponins, natriuretic peptides, and acylcarnitines.

Diagnosis

Diagnosis of myocardial metabolic alterations relies on a combination of clinical assessment, cardiac imaging, and metabolic profiling. Advanced techniques such as positron emission tomography (PET) using radiolabeled substrates (e.g., 18F-fluorodeoxyglucose for glucose metabolism) provide insights into in vivo myocardial substrate utilization. Cardiac magnetic resonance spectroscopy enables non-invasive assessment of myocardial energy stores and metabolic flux. Routine laboratory markers, while non-specific, may support the diagnosis when interpreted in the context of clinical and imaging findings.

Treatment & Management

Management strategies for myocardial dysfunction in critical illness should be individualized, focusing on optimizing hemodynamics, oxygen delivery, and metabolic milieu. Avoidance of excess catecholamine use, judicious glucose control, and early recognition of hypoperfusion are essential. Nutritional support strategies may be tailored to promote substrate flexibility, with ongoing research evaluating the impact of carbohydrate versus lipid-based feeding in the ICU. Pharmacological agents targeting mitochondrial function and metabolic pathways, such as trimetazidine, perhexiline, and ketone supplementation, are under investigation for their potential to restore metabolic homeostasis and improve cardiac performance.

Recent Advances / Emerging Therapies

Recent years have witnessed a surge in research exploring metabolic modulation as a therapeutic target in critical illness. Ketone body supplementation, currently under investigation in sepsis and heart failure, may provide a more efficient myocardial fuel under hypoxic conditions. Agents that activate PPAR pathways or enhance mitochondrial biogenesis have shown promise in preclinical models. Novel biomarkers derived from metabolomic profiling may allow earlier identification of patients at risk for adverse myocardial substrate shifts, facilitating personalized therapeutic approaches.

Guideline Recommendations

Current critical care guidelines, including those from the Surviving Sepsis Campaign and the European Society of Intensive Care Medicine, emphasize the importance of hemodynamic optimization and avoidance of hyperglycemia, but do not yet provide specific recommendations for metabolic modulation of myocardial substrate utilization. Ongoing clinical trials and emerging evidence will likely inform future updates, with anticipated incorporation of metabolic considerations into broader critical care algorithms.

Conclusion

Myocardial energy substrate shifts during critical illness represent a complex, multifactorial adaptation with significant clinical implications. Recognition of these metabolic changes is essential for optimizing cardiac function in the ICU and may inform the development of novel therapeutic strategies. Continued research into the mechanisms, diagnostics, and targeted interventions for myocardial metabolic dysfunction holds promise for improving outcomes in critically ill patients.